EBVaGC received significant benefit from the suggested ICI combined with CTLA-4 blockade over single immunotherapy, suggesting that tumor mutational burden and SMARCA4 mutations may be useful biomarkers for the prediction of ICI efficacy in patients with EBVaGC. The gene discussed is SMARCA4; the disease is neoplasm.